JGC
ABMD

J. Goldman & Co’s Abiomed Inc ABMD Stock Holding History

J. Goldman & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,833
Closed -$1.28M – 371
2020
Q1 		$1.28M Buy
+8,833
New +$1.47M 0.15% 129

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

J. Goldman & Co's ABMD Position: Q2 2020 in Review

J. Goldman & Co sold out of Abiomed Inc (ABMD) in Q2 2020, closing a stake of 8,833 shares — an estimated $1.28M sold.

J. Goldman & Co first reported a position in ABMD in Q1 2020 and held it in 1 quarter. The position peaked at $1.28M in Q1 2020. 460 funds tracked by Wall St. Rank hold ABMD as of Q2 2020.

  • J. Goldman & Co reported no remaining Abiomed Inc position as of Q2 2020 after selling out during the quarter.
  • J. Goldman & Co sold 8,833 Abiomed Inc shares in Q2 2020, an estimated $1.28M.
  • J. Goldman & Co first reported a position in Abiomed Inc in Q1 2020 and held it in 1 quarter.
  • J. Goldman & Co's Abiomed Inc position peaked at $1.28M in Q1 2020.
  • 460 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2020.

Based on J. Goldman & Co's 13F filing for Q2 2020, filed 14 Aug 2020.